Literature DB >> 22585465

Cognitive features 10 or more years after successful breast cancer survival: comparisons across types of cancer interventions.

Christopher M Nguyen1, Torricia H Yamada, Leigh J Beglinger, Joseph E Cavanaugh, Natalie L Denburg, Susan K Schultz.   

Abstract

BACKGROUND: The present study examined the long-term cognitive implications of cancer treatment among breast cancer survivors aged 65 years and older to better understand the long term implications of cancer treatment.
METHODS: Fifty-seven women survivors were compared with 30 healthy older female adult comparisons, matched in terms of age and education, with no history of cancer. Cancer survivors were also compared on the basis of treatment intervention, involving chemotherapy (n = 27) versus local therapy through surgery and radiation (n = 30).
RESULTS: As a group, the breast cancer survivors scored lower on measures of general cognitive function, working memory, psychomotor speed, and executive function when compared with the normal comparisons. Among the cancer survivors, those who received local therapy scored lower than the other survivors and normal comparisons on measures of verbal learning, visual perception and construction, as well as visual attention and short-term retention.
CONCLUSIONS: Our findings suggest that cognitive outcomes may involve greater age-related deficits among older cancer survivors compared with matched healthy subjects.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22585465      PMCID: PMC3475736          DOI: 10.1002/pon.3086

Source DB:  PubMed          Journal:  Psychooncology        ISSN: 1057-9249            Impact factor:   3.894


  23 in total

1.  Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma.

Authors:  Tim A Ahles; Andrew J Saykin; Charlotte T Furstenberg; Bernard Cole; Leila A Mott; Karen Skalla; Marie B Whedon; Sarah Bivens; Tara Mitchell; E Robert Greenberg; Peter M Silberfarb
Journal:  J Clin Oncol       Date:  2002-01-15       Impact factor: 44.544

Review 2.  Cognitive function and reproductive hormones in adjuvant therapy for breast cancer: a critical review.

Authors:  C M Bender; K K Paraska; S M Sereika; C M Ryan; S L Berga
Journal:  J Pain Symptom Manage       Date:  2001-05       Impact factor: 3.612

3.  A visual retention test for clinical use.

Authors:  A L BENTON
Journal:  Arch Neurol Psychiatry       Date:  1945-09

Review 4.  The potential for neuropsychology to inform functional outcomes research with breast cancer survivors.

Authors:  Stephanie A Reid-Arndt
Journal:  NeuroRehabilitation       Date:  2006       Impact factor: 2.138

5.  A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer.

Authors:  Angela Stewart; Catherine Bielajew; Barbara Collins; Matthew Parkinson; Eva Tomiak
Journal:  Clin Neuropsychol       Date:  2006-02       Impact factor: 3.535

6.  Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study.

Authors:  Arti Hurria; Carol Rosen; Clifford Hudis; Enid Zuckerman; Katherine S Panageas; Mark S Lachs; Matthew Witmer; Wilfred G van Gorp; Monica Fornier; Gabriella D'Andrea; Mark Moasser; Chau Dang; Catherine Van Poznak; Anju Hurria; Jimmie Holland
Journal:  J Am Geriatr Soc       Date:  2006-06       Impact factor: 5.562

7.  Cognitive impairment associated with adjuvant therapy in breast cancer.

Authors:  Catherine M Bender; Susan M Sereika; Sarah L Berga; Victor G Vogel; Adam M Brufsky; Karen K Paraska; Christopher M Ryan
Journal:  Psychooncology       Date:  2006-05       Impact factor: 3.894

8.  Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer.

Authors:  Jeffrey S Wefel; Angele K Saleeba; Aman U Buzdar; Christina A Meyers
Journal:  Cancer       Date:  2010-07-15       Impact factor: 6.860

9.  Cognitive impairments associated with breast cancer treatments: results from a longitudinal study.

Authors:  Catherine Quesnel; Josée Savard; Hans Ivers
Journal:  Breast Cancer Res Treat       Date:  2008-07-16       Impact factor: 4.872

10.  Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients.

Authors:  S B Schagen; M J Muller; W Boogerd; R M Rosenbrand; D van Rhijn; S Rodenhuis; F S A M van Dam
Journal:  Ann Oncol       Date:  2002-09       Impact factor: 32.976

View more
  15 in total

1.  Subjective and objective cognitive functioning among patients with breast cancer: effects of chemotherapy and mood symptoms.

Authors:  Yen-Hsuan Hsu; Vincent Chin-Hung Chen; Ching-Chuan Hsieh; Yi-Ping Weng; Ya-Ting Hsu; Han-Pin Hsiao; Wen-Ke Wang; Hong-Ming Chen; Jun-Cheng Weng; Shu-I Wu; Michael Gossop
Journal:  Breast Cancer       Date:  2020-10-08       Impact factor: 4.239

Review 2.  Systemic therapies and cognitive impairment for breast cancer: an overview of the current literature.

Authors:  Icro Meattini; Isacco Desideri; Giulio Francolini; Agnese Vannini; Marco Perna; Pietro Garlatti; Roberta Grassi; Lorenzo Livi
Journal:  Med Oncol       Date:  2017-03-31       Impact factor: 3.064

3.  The impact of APOE and smoking history on cognitive function in older, long-term breast cancer survivors.

Authors:  Tim A Ahles; Irene Orlow; Elizabeth Schofield; Yuelin Li; Elizabeth Ryan; James C Root; Sunita K Patel; Katrazyna McNeal; Alexandra Gaynor; Heidi Tan; Vani Katheria; Jessica Vazquez; Sergio Corrales-Guerrero; Keimya Sadeghi; Tiffany Traina; Arti Hurria
Journal:  J Cancer Surviv       Date:  2022-10-24       Impact factor: 4.062

4.  Blocking LLT1 (CLEC2D, OCIL)-NKRP1A (CD161) interaction enhances natural killer cell-mediated lysis of triple-negative breast cancer cells.

Authors:  Armando M Marrufo; Stephen O Mathew; Pankaj Chaudhary; Joseph D Malaer; Jamboor K Vishwanatha; Porunelloor A Mathew
Journal:  Am J Cancer Res       Date:  2018-06-01       Impact factor: 6.166

5.  Frontal hypometabolism in elderly breast cancer survivors determined by [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET): a pilot study.

Authors:  Laura L Boles Ponto; Yusuf Menda; Vincent A Magnotta; Torricia H Yamada; Natalie L Denburg; Susan K Schultz
Journal:  Int J Geriatr Psychiatry       Date:  2014-09-01       Impact factor: 3.485

6.  Cognitive problems among breast cancer survivors: loneliness enhances risk.

Authors:  Lisa M Jaremka; Juan Peng; Robert Bornstein; Catherine M Alfano; Rebecca R Andridge; Stephen P Povoski; Adele M Lipari; Doreen M Agnese; William B Farrar; Lisa D Yee; William E Carson; Janice K Kiecolt-Glaser
Journal:  Psychooncology       Date:  2014-04-11       Impact factor: 3.894

7.  Accelerated vascular aging and persistent cognitive impairment in older female breast cancer survivors.

Authors:  Barbara W Carlson; Melissa A Craft; John R Carlson; Wajeeha Razaq; Kelley K Deardeuff; Doris M Benbrook
Journal:  Geroscience       Date:  2018-05-26       Impact factor: 7.713

Review 8.  Four decades of chemotherapy-induced cognitive dysfunction: comprehensive review of clinical, animal and in vitro studies, and insights of key initiating events.

Authors:  Ana Dias-Carvalho; Mariana Ferreira; Rita Ferreira; Maria de Lourdes Bastos; Susana Isabel Sá; João Paulo Capela; Félix Carvalho; Vera Marisa Costa
Journal:  Arch Toxicol       Date:  2021-11-02       Impact factor: 5.153

9.  Cognitive function in cancer survivors: analysis of the 1999-2002 National Health and Nutrition Examination Survey.

Authors:  A M Williams; M C Janelsins; E van Wijngaarden
Journal:  Support Care Cancer       Date:  2015-11-09       Impact factor: 3.359

10.  Relationship between cognitive functioning and frailty in older breast cancer survivors.

Authors:  Tim A Ahles; Elizabeth Schofield; Yuelin Li; Elizabeth Ryan; James C Root; Sunita K Patel; Katrazyna McNeal; Alexandra Gaynor; Heidi Tan; Vani Katheria; Jessica Vazquez; Tiffany Traina; Arti Hurria
Journal:  J Geriatr Oncol       Date:  2021-08-05       Impact factor: 3.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.